Zeinab Panahi1, Asghar Abdoli2, Ghasem Mosayebi3, Mehdi Mahdavi4, Fariborz Bahrami4. 1. Department of Microbiology and Immunology, School of Medicine, Molecular and Medicine Research Center (MMRC), Arak University of Medical Sciences, P.O. Box: 38481-7-6941, Arak, Iran. 2. Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran. 3. Department of Microbiology and Immunology, School of Medicine, Molecular and Medicine Research Center (MMRC), Arak University of Medical Sciences, P.O. Box: 38481-7-6941, Arak, Iran. ghasemmosayebi@arakmu.ac.ir. 4. Department of Immunology, Pasteur Institute of Iran, Tehran, Iran.
Abstract
OBJECTIVE: To evaluate the combined effects of CpG oligodeoxynucleotides (CpG-ODNs) adjuvant and subcutaneous injection route on efficacy of a HIV-1-tat DNA vaccine candidate using BALB/c mice as an animal model. RESULTS: Evaluation of cellular and humoral immunity of mice injected subcutaneously with HIV-1-tat gene cloned into a pcDNA3.1 vector indicated that significant levels of IFN-γ cytokine secretion (900 pg/ml), lymphocyte proliferation (2.5 stimulation index) and IgG2a (1.45 absorbance 450 nm) production could be achieved. These indicators of stimulated cellular immunity were elicited 2 weeks after the last injection (P < 0.05). CONCLUSIONS: Formulation of HIV-1-tat DNA vaccine candidate with CpG-ODNs as an adjuvant while administrated subcutaneously are a promising approach to induce effective cellular immunity responses against HIV-1 infection.
OBJECTIVE: To evaluate the combined effects of CpG oligodeoxynucleotides (CpG-ODNs) adjuvant and subcutaneous injection route on efficacy of a HIV-1-tat DNA vaccine candidate using BALB/c mice as an animal model. RESULTS: Evaluation of cellular and humoral immunity of mice injected subcutaneously with HIV-1-tat gene cloned into a pcDNA3.1 vector indicated that significant levels of IFN-γ cytokine secretion (900 pg/ml), lymphocyte proliferation (2.5 stimulation index) and IgG2a (1.45 absorbance 450 nm) production could be achieved. These indicators of stimulated cellular immunity were elicited 2 weeks after the last injection (P < 0.05). CONCLUSIONS: Formulation of HIV-1-tat DNA vaccine candidate with CpG-ODNs as an adjuvant while administrated subcutaneously are a promising approach to induce effective cellular immunity responses against HIV-1 infection.
Entities:
Keywords:
CpG-ODNs; DNA vaccine; HIV vaccine; HIV-1; Subcutaneous injection; Tat